Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center Experience.
clinical response
lymphadenectomy
muscle-invasive bladder cancer
neoadjuvant chemotherapy
overall survival
robotic radical cystectomy
urothelial carcinoma
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
24 Aug 2020
24 Aug 2020
Historique:
received:
08
07
2020
revised:
07
08
2020
accepted:
19
08
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Response to neoadjuvant chemotherapy (NACT) has been proven to be an established prognostic factor after open radical cystectomy (ORC). We evaluated the impact of NACT on survival outcomes of a single-institution robotic radical cystectomy (RARC) series. From January 2012 to June 2020, 79 patients were identified. Baseline, demographic, perioperative, and pathologic data were described. Kaplan-Meier with the log-rank test was used to compare overall survival (OS) differences between complete, partial, and no-NACT responders, respectively. Univariable and multivariable regression analyses were performed to identify predictors of OS. Complete, partial, and absent response to NACT were recorded in 43 (54.4%), 21 (19%), and 15 (26.6%) patients, respectively. A complete response to NACT displayed a trend toward significant higher OS ( Complete response to NACT is associated with increased OS probability, but significant nodal residual disease remains the only independent predictor of OS after RARC.
Sections du résumé
BACKGROUND
BACKGROUND
Response to neoadjuvant chemotherapy (NACT) has been proven to be an established prognostic factor after open radical cystectomy (ORC). We evaluated the impact of NACT on survival outcomes of a single-institution robotic radical cystectomy (RARC) series.
METHODS
METHODS
From January 2012 to June 2020, 79 patients were identified. Baseline, demographic, perioperative, and pathologic data were described. Kaplan-Meier with the log-rank test was used to compare overall survival (OS) differences between complete, partial, and no-NACT responders, respectively. Univariable and multivariable regression analyses were performed to identify predictors of OS.
RESULTS
RESULTS
Complete, partial, and absent response to NACT were recorded in 43 (54.4%), 21 (19%), and 15 (26.6%) patients, respectively. A complete response to NACT displayed a trend toward significant higher OS (
CONCLUSIONS
CONCLUSIONS
Complete response to NACT is associated with increased OS probability, but significant nodal residual disease remains the only independent predictor of OS after RARC.
Identifiants
pubmed: 32847113
pii: jcm9092736
doi: 10.3390/jcm9092736
pmc: PMC7564756
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
J Clin Med. 2019 Aug 09;8(8):
pubmed: 31395826
Urol Oncol. 2020 Aug;38(8):684.e9-684.e15
pubmed: 32284255
J Clin Med. 2020 Feb 20;9(2):
pubmed: 32093240
Eur Urol. 2015 Feb;67(2):241-9
pubmed: 25257030
Urology. 2020 Aug;142:155-160
pubmed: 32268173
BJU Int. 2018 May;121(5):752-757
pubmed: 29281852
BJU Int. 2017 Apr;119(4):605-611
pubmed: 27743481
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):25-30
pubmed: 26977202
Eur Urol Focus. 2018 Jul;4(4):608-613
pubmed: 28753862
J Urol. 2020 Jan;203(1):57-61
pubmed: 31600114
Eur J Surg Oncol. 2018 Sep;44(9):1432-1438
pubmed: 29699838
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
BJU Int. 2020 Oct;126(4):464-471
pubmed: 32403199
J Urol. 2017 Aug;198(2):436-444
pubmed: 28336308
World J Urol. 2020 Apr;38(4):837-843
pubmed: 31190152
Expert Rev Anticancer Ther. 2020 Jul;20(7):603-614
pubmed: 32546025
Eur Urol Oncol. 2020 Apr;3(2):239-249
pubmed: 31668714
Eur Urol Focus. 2018 Nov 16;:
pubmed: 30455153
Eur Urol. 2020 Apr 29;:
pubmed: 32360052
Adv Chronic Kidney Dis. 2018 Jan;25(1):7-13
pubmed: 29499890
Eur Urol. 2017 Nov;72(5):660-664
pubmed: 28545841
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354
pubmed: 32135513
Minerva Urol Nefrol. 2020 Jan 07;:
pubmed: 31920065
Minerva Urol Nefrol. 2019 Dec;71(6):590-596
pubmed: 31619034
J Urol. 2019 Nov;202(5):927-935
pubmed: 31188729
Eur Urol. 2018 Jun;73(6):934-940
pubmed: 27780643
J Clin Med. 2020 Jun 23;9(6):
pubmed: 32585894